INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 212 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2019. The put-call ratio across all filers is 1.87 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $5,509,000 | -49.2% | 87,500 | +0.0% | 0.20% | -28.6% |
| Q4 2019 | $10,839,000 | -2.7% | 87,468 | -47.9% | 0.28% | -8.9% |
| Q3 2019 | $11,142,000 | +8.3% | 167,902 | +29.8% | 0.30% | +19.3% |
| Q2 2019 | $10,292,000 | -17.9% | 129,346 | +15.4% | 0.25% | -19.1% |
| Q1 2019 | $12,538,000 | +15.7% | 112,087 | +4.2% | 0.31% | +2.6% |
| Q4 2018 | $10,840,000 | -14.2% | 107,553 | +7.6% | 0.31% | +2.3% |
| Q3 2018 | $12,628,000 | -0.6% | 99,938 | -34.0% | 0.30% | -5.7% |
| Q2 2018 | $12,707,000 | +79.2% | 151,434 | +31.4% | 0.32% | +83.2% |
| Q1 2018 | $7,090,000 | +0.5% | 115,245 | -4.6% | 0.17% | +4.2% |
| Q4 2017 | $7,055,000 | – | 120,757 | – | 0.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |